BACKGROUND

Presence of the CYP2C19 loss-of-function (LoF) *2 allele is associated with reduced antiplatelet effect in clopidogrel-treated patients. Since about 50% of major adverse cardiac events occur within the first few days after percutaneous coronary intervention (PCI), a rapid CYP2C19*2 genotype result is important to individualise antiplatelet therapy at the start of treatment.

STUDY DESIGN

1. Ethical approval for the study was granted.
2. Following informed written consent, patients undergoing PCI with stent deployment for ACS or stable angina and who were candidates for DAPT were recruited by a clinical pharmacist researcher from the catheterisation laboratory over a 3-month period (October to December 2014).
3. Exclusion criteria were patients < 18 and > 75 years, body weight < 60 kg, history of stroke or transient ischaemic attack, active bleeding, coagulation or platelet disorders and/or chronic liver disease.

RESULTS

Patient baseline characteristics

The total patient cohort consisted of 34 patients. Twenty-five patients were male and 9 were female, mean age was 66 years (range 49-75 years) and all patients were Caucasian.

CYP2C19 genotype results

Thirteen patients (38%) were genotyped as carriers of the CYP2C19 LoF *2 allele (Table 1).

CONCLUSIONS

The Spartan RX assay rapidly identifies carriers of the LoF *2 allele (13 patients in this cohort), is user-friendly requiring minimal training and is portable enabling testing at the patient's bedside. The main limitation is the cost of the tests. According to the Clinical Pharmacogenetics Implementation Consortium (CPIC) recommendations for CYP2C19 genotype and clopidogrel therapy these patients are candidates for a newer and more potent P2Y12 receptor, such as prasugrel. This assay can be implemented for pharmacist-led CYP2C19*2 genotype-guided personalisation of antiplatelet therapy in the critical period post-PCI.

Table 1: Distribution of CYP2C19 *2 allele (N=34)

<table>
<thead>
<tr>
<th>CYP2C19 genotype</th>
<th>Number of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-carrier of *2 allele</td>
<td>21</td>
</tr>
<tr>
<td>Carrier of one *2 allele</td>
<td>12</td>
</tr>
<tr>
<td>Carrier of two *2 alleles</td>
<td>1</td>
</tr>
</tbody>
</table>

*Candidates for alternative antiplatelet therapy to clopidogrel

Acknowledgements

This research was carried out in collaboration with all the cardiologists, doctors, nurses and staff at the Department of Cardiology, MGH. This research was supported by the University of Malta Faculty of Medicine and Surgery Dean’s Initiative, Technoline Ltd., Malta Heart Foundation, Orme Scientific Ltd. and the University of Malta Research Grant on Point-of-Care Testing.